Editorial: Pathophysiology of diabetic kidney disease
Frontiers in Clinical Diabetes and Healthcare · 29.05.2026 · 7
DOI: 10.3389/fcdhc.2026.1872162 ↗Kurz gefasst
Editorial in der Zeitschrift Frontiers in Clinical Diabetes and Healthcare, online erschienen am 29.05.2026. Verfasst von Oscar Lorenzo. Beteiligte Einrichtung: Laboratory of Vascular Pathology and Diabetes, IIS Fundación Jiménez Díaz, Autónoma University, Spanish Biomedical Research Centre in Diabetes and As…. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Moreover, three studies provide complementary insights into the intersection of diabetes and kidney transplantation. Transplants using kidneys with pre-existing diabetic nephropathy may achieve acceptable long-term outcomes. Perioperative hyperglycemia and early insulin requirements appear modifiable and may improve the incidence and course of post-transplant diabetes. These observations underscore the potential for personalized peri-transplant metabolic management, another emerging application of precision nephrology.In addition, one of the most compelling contributions of this collection is the identification of multiple biomarkers (metabolic, lipid-based, oxidative, immunologic) that refine risk prediction and disease mechanisms. The study of the non-HDL-C/HDL-C ratio (NHHR) reveals a nonlinear, L-shaped association with DKD risk, with a critical threshold at NHHR ≤ 2.82. Atherogenic dyslipidemia may therefore be not merely a cardiovascular risk factor but a direct modulator of renal vulnerability. Indeed, lipotoxicity injures podocytes and tubular cells, highlighting PCSK9-targeted therapies as promising nephroprotective strategies. Similarly, insulin-resistance markers (i.e., TyG, TyG-BMI, and TG/HDL-C) demonstrate strong predictive value for DKD, particularly in individuals with poor glycemic control. The sex-specific interaction observed for TG/HDL-C adds nuance and may guide more personalized risk assessment. In this line, lower bilirubin levels correlate with worse renal function, higher proteinuria, and poorer renal survival after DKD. Even subtle variations within the physiological range may carry prognostic significance. Along the same mechanistic axis, ACSL4, a ferroptosis-related enzyme, predicts rapid eGFR decline. AKT3 and FYN, linked to PANoptosis, show diagnostic value and correlate with GFR and BUN. MCUR1, CYP27B1, and G6PC, regulators of M2 macrophage polarization and efferocytosis, emerge also as key diagnostic genes for inflammation resolution. Finally, NONO, associated with MMP-9 and fibrosis, is strongly linked to poor renal prognosis. Therefore, these biomarkers illustrate how molecular phenotyping can identify high-risk subgroups, refine prognosis, and potentially guide targeted interventions-core components of precision nephrology.Nevertheless, the biomarker thresholds, risk associations, and mechanistic findings may not be directly generalizable across different ethnicities, healthcare settings, or stages of CKD. These limitations underscore the need for validation in diverse cohorts before these markers can be fully integrated into precision-based clinical practice.In conclusion, DKD is no longer an inevitable late complication of diabetes. It is transitioning from a clinically defined condition based on albuminuria and eGFR to a biologically stratified disease characterized by molecular signatures, immune pathways, and microvascular dysfunction. A new generation of biomarkers may enable earlier detection and more personalized intervention, marking a decisive step toward precision approaches to DKD management.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratory of Vascular Pathology and Diabetes, IIS Fundación Jiménez Díaz, Autónoma University, Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM) Network, Madrid, Spain.
Zitieren
APA
Lorenzo, O. (2026). Editorial: Pathophysiology of diabetic kidney disease. Frontiers in Clinical Diabetes and Healthcare, 7. https://doi.org/10.3389/fcdhc.2026.1872162
Vancouver
Lorenzo O. Editorial: Pathophysiology of diabetic kidney disease. Frontiers in Clinical Diabetes and Healthcare. 2026;7. doi:10.3389/fcdhc.2026.1872162
BibTeX
@article{Lorenzo2026,
author = {Lorenzo, Oscar},
title = {Editorial: Pathophysiology of diabetic kidney disease},
journal = {Frontiers in Clinical Diabetes and Healthcare},
year = {2026},
volume = {7},
doi = {10.3389/fcdhc.2026.1872162}
}
EUVIMED